top of page

THC microdosing reduces chronic pain in world-first clinical trial


Israeli pharma-tech company, Syqe Medical, set out to test a first-of-its-kind product that reportedly enables precise dosing of low-levels of THC to control pain.


A randomized, double‐blinded, and placebo‐controlled trial recruited a cohort of 27 subjects with chronic neuropathic pain. Across three separate test days each subject received one inhaled dose, containing either 500 micrograms (0.5 mg) of THC, 1,000 micrograms (1 mg) of THC, or a placebo.


“Both doses, but not the placebo, demonstrated a significant reduction in pain intensity compared with baseline and remained stable for 150‐min,” the researchers write in the published study. “The 1‐mg dose showed a significant pain decrease compared to the placebo.”


"We can conclude from the study results that low doses of cannabis may provide desirable effects while avoiding cognitive debilitations, significantly contributing to daily functioning, quality of life, and safety of the patient,” says Elon Eisenberg, lead research on the project, from the Technion-Israel Institute of Technology. “The doses given in this study, being so low, mandate very high precision in the treatment modality.”

bottom of page